Tesser J, et al. - Researchers evaluated intravenous golimumab + methotrexate (MTX) for its safety and efficacy in patients with active rheumatoid arthritis (RA) aged < 65 years and those ≥ 65 years who were enrolled in the GO-FURTHER study. In phase 3, double-blind, randomized, placebo-controlled GO-FURTHER trial, intravenous (IV) golimumab 2 mg/kg + MTX or placebo + MTX were administered to patients with active RA at weeks 0 and 4, then every 8 weeks thereafter (with crossover to golimumab at week 16 [early escape] or week 24 [per-protocol]). The final golimumab infusion was done at week 100. In GO-FURTHER, patients < 65 years and patients ≥ 65 years showed similar American College of Rheumatology response rates within each treatment group. Elderly patients had adverse events, which were similar to the known safety profile of IV golimumab. The risk of infections increases in the elderly in relation to immunosenescence. They noted numerically higher incidence of serious infections in elderly patients. Among golimumab-treated patients, they observed six malignancies which all occurred in patients < 65 years.